Answers are grounded in this paper and cite their sources.
Twenty-two patients with polymyositis and dermatomyositis were treated with combined prednisone and intravenous methotrexate when moderate to high-dose cortisone alone was ineffective in controlling disease activity. Definite clinical improvement was noted in 17 or 77% of the patients. Those patients responding to therapy normalized their muscle enzymes (creatine Phosphokinase, CPK) after a mean period of 10 weeks; moreover, the onset of muscle strength improvement was noted at an average of 13 weeks. A "steroid-sparing" effect was noted in that the prednisone dose has been decreased from 47 mg/day (premethotrexate) to 12 mg/day at 15 months follow-up. Toxicity to methotrexate was minor and reversible. After an average treatment period of more than 1 year, and a total average dose of over 1 g methotrexate, clinical and laboratory hepatotoxicity was not found. Intravenous methotrexate is an important treatment for polymyositis and dermatomyositis.
No takes yet. Share an insight, caveat, or question.
Allan L. Metzger (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: